89bio to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

SAN FRANCISCO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that Company’s Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 24^th Annual Global Investment Conference on Monday, September 12, 2022 at 4:00 PM ET.

The webcast of the presentation will be accessible here and in the investor section of 89bio’s website.

About 89bio 
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco with operations in Herzliya, Israel. For more information, visit www.89bio.com or follow the company on LinkedIn.

Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com

Media Contact:
Lauren Barbiero
Real Chemistry
lbarbiero@realchemistry.com